ImmunityBio (IBRX) announced new findings from the Phase 2 QUILT-3.055 study, presented at the IASLC 2025 World Conference on Lung Cancer. The study demonstrated that ANKTIVA reverses lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer. This reversal resulted in significant prolonged median overall survival. In patients with absolute lymphocyte counts greater than 1,500 cells/microL, a statistically significant prolonged median overall survival of 21.1 months was observed.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?
- ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?
- ImmunityBio announces early findings from Anktiva pilot study
- ImmunityBio announces Anktiva trial
- ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment